eISSN: 1644-4124
ISSN: 1426-3912
Central European Journal of Immunology
Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
1/2024
vol. 49
 
Share:
Send email
Share:
Clinical immunology

A study on the side effects caused by the Pfizer/BioNTech COVID-19 vaccine: Focus on IgG antibodies and serological biomarkers

Kameran M. Ali
1
,
Ayad M. Ali
2
,
Peshnyar M. Atta
3
,
Kochar I. Mahmood
4
,
Hassan M. Rostam
5

1.
Medical Laboratory Technology Department, Kalar Technical College, Garmian Polytechnic University, Kalar, Iraq
2.
Department of Chemistry, College of Science, University of Garmian, Kalar, Iraq
3.
Medical Laboratory Science Department, Komar University of Science and Technology, Sulaimania, Iraq
4.
Medical Laboratory Science Department, College of Science, Charmo University, Chamchamal, Kurdistan region, Iraq
5.
Centauri Therapeutics LTD, Iraq; Registered address: First Floor, 5 Fleet Place, London, EC4M 7RD
Cent Eur J Immunol 2024; 49 (1): 2 - 10
DOI: https://doi.org/10.5114/ceji.2024.136382
Online publish date: 2024/04/09
Article files
- A study on the side (1).pdf  [0.67 MB]
- Supplementary material.pdf  [0.31 MB]
Get citation
 
PlumX metrics:
 
1. World Health Organization (2023). WHO Coronavirus (COVID-19) Dashboard. Available from https://covid19. who.int/
2. Ali KM, Rashid PMA, Ali AM, et al. (2023): Clinical outcomes and phylogenetic analysis in reflection with three predominant clades of SARS-CoV-2 variants. Eur J Clin Invest 53: e14004.
3. Singh D, Yi SV (2021): On the origin and evolution of SARS-CoV-2. Exp Mol Med 53: 537-547.
4. Bareiß A, Uzun G, Mikus M, et al. (2023): Vaccine side effects in health care workers after vaccination against SARS-CoV-2: Data from TüSeRe: exact study. Viruses 15: 65.
5. Ali AM, Rostam HM, Fatah MH, et al. (2022): Serum troponin, D-dimer, and CRP level in severe coronavirus (COVID-19) patients. Immun Inflamm Dis 10: e582.
6. R&D Blueprint. COVID-19 vaccine tracker and landscape. Available from https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines
7. Riad A, Pokorná A, Mekhemar M, et al. (2021): Safety of chadox1 ncov-19 vaccine: Independent evidence from two EU states. Vaccines 9: 1-12.
8. Leav B, Straus W, White P, et al. (2022): A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Moderna COVID-19 Vaccine (mRNA-1273). Vaccine 40: 5275-5293.
9. Mathieu E, Ritchie H, Ortiz-Ospina E, et al. (2021): A global database of COVID-19 vaccinations. Nat Hum Behav 5: 947-953.
10. Bar-On YM, Goldberg Y, Mandel M, et al. (2021): Protection of BNT162b2 vaccine booster against Covid-19 in Israel. N Engl J Med 385: 1393-1400.
11. Ali AM, Tofiq AM, Rostam HM, et al. (2022): Disease severity and efficacy of homologous vaccination among patients infected with SARS-CoV-2 Delta or Omicron VOCs, compared to unvaccinated using main biomarkers. J Med Virol 94: 5867-5876.
12. Ali AM, Tofiq AM, Rostam HM, Ali KM TH (2023): Reply to Letter to the Editor on disease severity and efficacy of homologous vaccination among patients infected with SARS-CoV-2 Delta or Omicron VOCs, compared to unvaccinated using main biomarkers. J Med Virol 95: e28313.
13. Ali AM, Tofiq AM, Rostam HM, Ali KM TH (2023): Corrigendum on “Disease severity and efficacy of homologous vaccination among patients infected with SARS-CoV-2 Delta or Omicron VOCs, compared to unvaccinated using main biomarkers”. J Med Virol 96: e28824.
14. Ali AM, Ali KM, Fatah MH, et al. (2021): SARS-CoV-2 reinfection in patients negative for immunoglobulin G following recovery from COVID-19. New Microbes New Infect 43: 100926.
15. Ebinger JE, Fert-Bober J, Printsev I, et al. (2021): Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2. Nat Med 27: 981-984.
16. El-Shitany NA, Harakeh S, Badr-Eldin SM, et al. (2021): Minor to moderate side effects of Pfizer-BioNTech COVID-19 vaccine among Saudi residents: A retrospective cross-sectional study. Int J Gen Med 14: 1389-1401.
17. Schulz JB, Berlit P, Diener HC, et al. (2021): COVID-19 vaccine-associated cerebral venous thrombosis in Germany. Ann Neurol 90: 627-639.
18. Castells MC, Phillips EJ (2021): Maintaining safety with SARS-CoV-2 vaccines. N Engl J Med 384: 643-649.
19. Polack FP, Thomas SJ, Kitchin N, et al. (2020): Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 383: 2603-2615.
20. Ali KM, Ali AM, Tawfeeq HM, et al. (2021): Hypoalbuminemia in patients following their recovery from severe coronavirus disease 2019. J Med Virol 93: 4532-4536.
21. Ali AM, Tofiq AM, Rostam HM, et al. (2023): Response to comments to the editor on “Disease severity and efficacy of homologous vaccination among patients infected with SARS-CoV-2 Delta or Omicron VOCs, compared to unvaccinated using main biomarkers”. J Med Virol 95: e28820.
22. Meo SA, Bukhari IA, Akram J, et al. (2021): COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines. Eur Rev Med Pharmacol Sci 25: 1663-1669.
23. Larson HJ, Cooper LZ, Eskola J, et al. (2011): Addressing the vaccine confidence gap. Lancet 378: 526-535.
24. Menni C, Klaser K, May A, et al. (2021): Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study. Lancet Infect Dis 21: 939-949.
25. Choi WS, Cheong HJ (2021): COVID-19 vaccination for people with comorbidities. Infect Chemother 53: 155-158.
26. Mallhi TH, Khan YH, Butt MH, et al. (2022): Surveillance of side effects after two doses of COVID-19 vaccines among patients with comorbid conditions: A sub-cohort analysis from Saudi Arabia. Medicina (Kaunas) 58: 1799.
27. Bergwerk M, Gonen T, Lustig Y, et al. (2021): Covid-19 breakthrough infections in vaccinated health care workers. N Engl J Med 385: 1474-1484.
28. Lustig Y, Sapir E, Regev-Yochay G, et al. (2021): BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers. Lancet Respir Med 9: 999-1009.
29. Gilbert PB, Montefiori DC, McDermott AB, et al. (2022): Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science 375: 43-50.
30. Guzmán-Martínez O, Guardado K, de Guevara EL, et al. (2021): Igg antibodies generation and side effects caused by ad5-ncov vaccine (Cansino biologics) and bnt162b2 vaccine (pfizer/biontech) among mexican population. Vaccines (Basel) 9: 999.
31. Soiza RL, Scicluna C, Thomson EC (2021): Efficacy and safety of COVID-19 vaccines in older people. Age Ageing 50: 279-283.
32. Brüssow H (2021): COVID-19: vaccination problems. Environ Microbiol 23: 2878-2890.
33. Zurac SB, Nichita L, Mateescu B, et al. (2021): COVID 19 vaccination and IgG and IgA antibody dynamics in healthcare workers. Mol Med Rep 24: 578.
34. Ruggiero A, Piubelli C, Calciano L, et al. (2022): SARS-CoV-2 vaccination elicits unconventional IgM specific responses in naïve and previously COVID-19-infected individuals. EBioMedicine 77: 103888.
35. Zurac S, Vladan C, Dinca O, et al. (2022): Immunogenicity evaluation after BNT162b2 booster vaccination in healthcare workers. Sci Rep 12: 12716.
36. Müller L, Andrée M, Moskorz W, et al. (2021): Age-dependent immune response to the BioNTech/Pfizer BNT162b2 coronavirus disease 2019 vaccination. Clin Infect Dis 73: 2065-2072.
37. Barin B, Kasap U, Selçuk F, et al. (2022): Comparison of SARS-CoV-2 anti-spike receptor binding domain IgG antibody responses after CoronaVac, BNT162b2, ChAdOx1 COVID-19 vaccines, and a single booster dose: a prospective, longitudinal population-based study. Lancet Microbe 3: e274-e283.
38. Fateh HL, Kamari N, Ali AM, et al. (2023): Association between diet quality and BMI with side effects of Pfizer-BioNTech COVID-19 vaccine and SARS-CoV-2 immunoglobulin G titers. Nutr Food Sci 53: 738-751.
39. Sing CW, Tang CTL, Chui CSL, et al. (2022): COVID-19 vaccines and risks of hematological abnormalities: Nested case-control and self-controlled case series study. Am J Hematol 97: 470-480.
40. Makris M, Pavord S, Lester W, et al. (2021): Vaccine-induced immune thrombocytopenia and thrombosis (VITT). Res Pract Thromb Haemost 5: 2-5.
41. Schultz NH, Sørvoll IH, Michelsen AE, et al. (2021): Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination. N Engl J Med 384: 2124-2130.
42. Nazy I, Sachs UJ, Arnold DM, et al. (2021): Recommendations for the clinical and laboratory diagnosis of VITT against COVID-19: Communication from the ISTH SSC Subcommittee on Platelet Immunology. J Thromb Haemost 19: 1585-1588.
43. Uaprasert N, Watanaboonyongcharoen P, Vichitratchaneekorn R, et al. (2021): Prevalence of thrombocytopenia, anti-platelet factor 4 antibodies and D-dimer elevation in Thai people after ChAdOx1 nCoV-19 vaccination. Res Pract Thromb Haemost 5: 1-6.
44. Klok FA, Pai M, Huisman MV, Makris M (2022): Vaccine-induced immune thrombotic thrombocytopenia. Lancet Haematol 9: e73-80.
45. Ali HN, Ali KM, Rostam HM, et al. (2022): Clinical laboratory parameters and comorbidities associated with severity of coronavirus disease 2019 (COVID-19) in Kurdistan Region of Iraq. Pract Lab Med 31: e00294.
46. Ali AM, Abdlwahid RF, Ali KM, et al. (2024): The influence of SARS-CoV-2 on male reproduction and men’s health. Eur J Clin Invest 54: e14097.
47. Posthouwer D, Voorbij HAM, Grobbee DE, et al. (2004): Influenza and pneumococcal vaccination as a model to assess C-reactive protein response to mild inflammation. Vaccine 23: 362-365.
48. Koenig W, Sund M, Fröhlich M, et al. (1999): C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 99: 237-243.
49. McDade TW, Borja JB, Kuzawa CW, et al. (2015): C-reactive protein response to influenza vaccination as a model of mild inflammatory stimulation in the Philippines. Vaccine 33: 2004-2008.
Copyright: © 2024 Polish Society of Experimental and Clinical Immunology This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.

Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.